Weight-loss use is not appropriate during pregnancy, and both are not recommended in severe gastroparesis
Program Highlights * Physician-guided medication selection between semaglutide and tirzepatide based on your individual profile * All-inclusive pricing: $179 for the first month, $299 ongoing, covering consultation, prescription (when appropriate), medication, shipping, and ongoing support * Same-day physician review for most patients * Home delivery in 3-5 business days through licensed pharmacies * 24/7 clinical support via messaging and video * Flexibility to switch medications if you plateau or experience tolerability issues Disclaimer: Pricing may change at any time
Clinical trials show that patients on Wegovy (semaglutide 2.4 mg) achieve average weight loss of approximately 15% in non-diabetic populations (somewhat lower in those with type 2 diabetes), though individual results vary
Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk
First, SELECT was designed as a CV outcomes trial and not a weight-loss trial, and weight loss was only a supportive secondary endpoint in the trial design
Semaglutide is an FDA-approved medication originally developed for managing type 2 diabetes